APA (7th ed.) Citation

Shah, R. R. (2008). If a drug deemed ‘safe’ in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed? Pharmacology & therapeutics (Oxford), 119(2), 215-221. https://doi.org/10.1016/j.pharmthera.2008.03.002

Chicago Style (17th ed.) Citation

Shah, Rashmi R. "If a Drug Deemed ‘safe’ in Nonclinical Tests Subsequently Prolongs QT in Phase 1 Studies, How Can Its Sponsor Convince Regulators to Allow Development to Proceed?" Pharmacology & Therapeutics (Oxford) 119, no. 2 (2008): 215-221. https://doi.org/10.1016/j.pharmthera.2008.03.002.

MLA (9th ed.) Citation

Shah, Rashmi R. "If a Drug Deemed ‘safe’ in Nonclinical Tests Subsequently Prolongs QT in Phase 1 Studies, How Can Its Sponsor Convince Regulators to Allow Development to Proceed?" Pharmacology & Therapeutics (Oxford), vol. 119, no. 2, 2008, pp. 215-221, https://doi.org/10.1016/j.pharmthera.2008.03.002.